NOVEL CONCEPT IRON DEFICIENCY ANEMIA THERAPEUTIC AGENT
iNtRON has a Heme-Iron production technology that does not utilize the blood of slaughtered animals such as the blood from swine. Heme-Iron produced through iNtRON’s technology was labeled Porphyrin-Fe.
Porphyrin-Fe is structurally identical to that of Heme found in human hemoglobin while offering superior bioavailability compared to that of conventional iron supplements.
Despite Porphyrin-Fe’s higher bioavailability, Porphyrin-Fe doesn’t have the infection risks traditionally associated with conventional Heme-iron products. Traditional Heme-iron products are manufactured using animal derived components while Porphyrin-Fe uses an entirely synthetic production process.
Traditional Heme-iron products are generally 90% protein which could lead to unintended weight gain. Because Porphyrin-Fe does not contain any protein moieties, the risk of excessive protein intake is negated for persons who are calorie concerned.
Unlike traditional Heme-iron products, consumers of Porphyrin-Fe do not encounter the negative “fish-like” smells associated with Heme-iron products.
ADVANTAGES OF PORPHYRIN-FE
Porphyrin-Fe has a superior level of bioavailability compared to that of existing iron supplements. Porphyrin-Fe is directly used as a precursor for hemoglobin synthesis upon administration. In contrast, existing iron supplements must be reabsorbed after being degraded as ferrous ion upon administration.
It is suitable during dietary therapy because it contains neither carbohydrates (sugars) nor proteins.
Porphyrin-Fe supplies higher iron content per gram compared to existing Heme-iron products manufactured from animal products.
Usual side effects associated with existing iron supplements such as maldigestion, constipation and absorption fluctuation are not associated with Porphyrin-Fe.
There is no risk of exposure to pathogens (non-specific protein or animal derived) as Porphyrin-Fe isn’t manufactured using the blood of slaughtered animals.
Finally, because Porphyrin-Fe contains no animal derived substances, it complies with vegetarian dietary ethics and is free from any religious limitation as could found in Islam or Judaism.
OUR SHORT TERM GOAL IS FOR AN IRON SUPPLEMENT OR AN ANEMIA TREATMENT TO BE DEVELOPED.
OUR LONG TERM GOAL IS FOR THE DEVELOPMENT OF A PRACTICAL ARTICIFIAL BLOOD MEDICAL SOLUTION.
THE WORLDWIDE INTRAVENOUS IRON SUPPLEMENT INJECTION MARKET VALUE IS VALUED AT 1.2 BILLION USD AS OF 2014, AND IT IS PREDICTED TO REACH 1.8 BILLION USD BY 2020.
CONSIDERING THE MARKET SHARE OF INTRAVENOUS IRON SUPPLEMENT INJECTION, WHICH IS 15.4% OF TOTAL IRON SUPPLEMENT MARKET, THE TOTAL IRON SUPPLEMENT MARKET SCALE IN 2020 WILL BE AROUND 10 BILLION USD.
iNtODEWORLD, Inc is the US subsidiary of iNtRON Biotechnology, Inc.